A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese Participants

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Dose of MK-8507 and Multiple Once Weekly Dose of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese Participants

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250655

Enrollment

Registered

2026-01-19

Start date

2026-04-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Interventions

Single dose of MK-8507 100, 200 and 400 mg or placebo Multiple weekly doses of MK-8591B (Islatravir/MK-8507) 2 mg/200 mg or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male and female participants between the ages of 18 and 55 years

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Safety (Adverse events, discontinuation of study intervention due to adverse events), Pharmacokinetics	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026